Allergan (AGN) Comments on Namenda XR Patent Litigation; Will Depend Appeals Court Case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
September 29, 2016 9:29 AM EDTDUBLIN, Sept. 29, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following announcement of FDA final ANDA approval by Lupin.
Photo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"As announced on September 10, 2015, Allergan's Forest Laboratories subsidiaries and its licensors announced a settlement agreement regarding their Namenda XR ANDA litigation with Amneal Pharmaceuticals as first filer and... More
